title: The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.
abstract: Simvastatin is among the most commonly used prescription medications for cholesterol reduction. A single coding single-nucleotide polymorphism, rs4149056T>C, in SLCO1B1 increases systemic exposure to simvastatin and the risk of muscle toxicity. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for simvastatin based on SLCO1B1 genotype. This article is an update to the 2012 Clinical Pharmacogenetics Implementation Consortium guideline for SLCO1B1 and simvastatin-induced myopathy.
authors.affiliation: Pharmaceutical Sciences Department, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
authors.forename: L B
authors.initials: LB
authors.lastname: Ramsey
authors.affiliation: 1] Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Denver, Colorado, USA [2] Clinical Pharmacy Services, Kaiser Permanente Colorado, Denver, Colorado, USA.
authors.forename: S G
authors.initials: SG
authors.lastname: Johnson
authors.affiliation: Pharmaceutical Sciences Department, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
authors.forename: K E
authors.initials: KE
authors.lastname: Caudle
authors.affiliation: Pharmaceutical Sciences Department, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
authors.forename: C E
authors.initials: CE
authors.lastname: Haidar
authors.affiliation: Department of Medicine, Duke University, Durham, North Carolina, USA.
authors.forename: D
authors.initials: D
authors.lastname: Voora
authors.affiliation: 1] IMAGENETICS, Sanford Medical Center, Fargo, North Dakota, USA [2] Department of Medicine, University of North Dakota, Fargo, North Dakota, USA.
authors.forename: R A
authors.initials: RA
authors.lastname: Wilke
authors.affiliation: Department of Clinical Pharmacy and Outcomes Sciences, South Carolina College of Pharmacy, Columbia, South Carolina, USA.
authors.forename: W D
authors.initials: WD
authors.lastname: Maxwell
authors.affiliation: Personalized Medicine Institute, Moffitt Cancer Center, Tampa, Florida, USA.
authors.forename: H L
authors.initials: HL
authors.lastname: McLeod
authors.affiliation: Atherosclerosis Research, Children's Hospital Oakland Research Institute, Oakland, California, USA.
authors.forename: R M
authors.initials: RM
authors.lastname: Krauss
authors.affiliation: 1] Oates Institute for Experimental Therapeutics, Vanderbilt University Medical Center, Nashville, Tennessee, USA [2] Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University, Nashville, Tennessee, USA.
authors.forename: D M
authors.initials: DM
authors.lastname: Roden
authors.affiliation: 1] Oates Institute for Experimental Therapeutics, Vanderbilt University Medical Center, Nashville, Tennessee, USA [2] Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University, Nashville, Tennessee, USA.
authors.forename: Q
authors.initials: Q
authors.lastname: Feng
authors.affiliation: Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics and Division of Cardiovascular Medicine, University of Florida, Gainesville, Florida, USA.
authors.forename: R M
authors.initials: RM
authors.lastname: Cooper-DeHoff
authors.affiliation: Department of Genetics, Stanford University, Palo Alto, California, USA.
authors.forename: L
authors.initials: L
authors.lastname: Gong
authors.affiliation: Department of Genetics, Stanford University, Palo Alto, California, USA.
authors.forename: T E
authors.initials: TE
authors.lastname: Klein
authors.affiliation: Department of Medical Sciences, Clinical Pharmacology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
authors.forename: M
authors.initials: M
authors.lastname: Wadelius
authors.affiliation: 1] Department of Clinical Pharmacology, University of Helsinki and HUSLAB, Helsinki University Central Hospital, Helsinki, Finland [2] King Abdulaziz University , Jeddah, Saudi Arabia.
authors.forename: M
authors.initials: M
authors.lastname: Niemi
mesh_terms: D004347:Drug Interactions; D005838:Genotype; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D027381:Liver-Specific Organic Anion Transporter 1; D009135:Muscular Diseases / Q000139:chemically induced*; D027361:Organic Anion Transporters / Q000235:genetics*; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D019821:Simvastatin / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D027381:Liver-Specific Organic Anion Transporter 1; D027361:Organic Anion Transporters; C503999:SLCO1B1 protein, human; D019821:Simvastatin